Umar Cheema
Pain Medicine · Albuquerque, NMNPI 1164919437
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Abbott at 52.1% of the total. Reporting peaked in 2023 at $1,823 and has fallen 86.5% since, to $246 in 2025.
Across 67 payments — averaging $52.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Nevro Corp.$984
- Stratus Medical, LLC$204
- Boston Scientific$196
- Medtronic$157
- Globus Medical$66
- plus $85 from 3 others
What the payments were for
- Food & beverage$3,529100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 35 | $1,838 |
| Nevro Corp. | 19 | $984 |
| Stratus Medical, LLC | 2 | $204 |
| Boston Scientific | 2 | $196 |
| Medtronic | 3 | $157 |
| Globus Medical | 3 | $66 |
| SPR Therapeutics, Inc | 1 | $31 |
| Avanos Medical | 1 | $30 |
| Amgen | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,529 in reported general payments places this provider in the 60th percentile of 36 pain medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 85 | $1,784 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 92 | $1,686 |
| Pregabalin | 28 | $1,062 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 23 | $1,003 |
| Baclofen | 63 | $770 |
| Tizanidine Hcl | 35 | $520 |
| Gabapentin | 35 | $452 |
| Tramadol Hcl | 40 | $378 |
| Cyclobenzaprine Hcl | 14 | $159 |
| Naproxen | 15 | $157 |
| Meloxicam | 24 | $157 |
| Methocarbamol | 12 | $104 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Albuquerque
- John WatkinsAlbuquerque$22K
- Craig RumbaughAlbuquerque$11K
- Eugene KoshkinAlbuquerque$10K
- Matthew BergstenAlbuquerque$7K
- Lauren HarrisAlbuquerque$6K
- Melissa MerhegeAlbuquerque$5K
- Jeremy ChastainAlbuquerque$5K
- Joshu RaitenAlbuquerque$4K
- Thomas WhalenAlbuquerque$4K
- Matthew ValerianoAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.